Patient-centered management of chemotherapy-induced nausea and vomiting

Cancer Control

Volumn 19, Issue 2 SUPPL., 2012, Pages 10-15

  Grunberg, Steven ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALTRETAMINE; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; IMATINIB; IRINOTECAN; MELPHALAN; METHOTREXATE; NAVELBINE; NEUROKININ 1 RECEPTOR ANTAGONIST; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PEMETREXED; PENTOSTATIN; PROCARBAZINE; ROMIDEPSIN; SEROTONIN 3 ANTAGONIST; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG;

CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CLINICAL ASSESSMENT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG METABOLISM; EVIDENCE BASED PRACTICE; HUMAN; INCIDENCE; NAUSEA; NAUSEA AND VOMITING; PATIENT CARE; PHARMACOGENOMICS; PRESCRIPTION; QUALITY OF LIFE; REVIEW; SOCIAL SUPPORT; STRATEGIC PLANNING; TREATMENT RESPONSE;

EID: 84859446386     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327481201902s03     Document Type: Review

References (31)

1. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358(23):2482-2494.
2. Kris MG, Gralla RJ, Clark RA, et al. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985;3(10):1379-1384.
3. Grunberg SM, Deuson RR, Mavros P, et al. Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer. 2004;100(10):2261-2268.
4. De Jongh-Garcia C, Poli S, Ananth C, et al. Health care provider perception of nausea and vomiting and patients' reported incidence: the Venezuela Emesis Registry. Support Care Cancer. 2005;13(6):414-415. Abstract.
5. Erazo Valle A, Wisniewski T, Figueroa Vadillo JI, et al. Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed. Curr Med Res Opin. 2006;22(12):2403-2410.
6. Liau CT, Chu NM, Liu HE, et al. Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs patients' reported outcomes. Support Care Cancer. 2005;13(5):277-286.
7. Molassiotis A, Coventry PA, Stricker CT, et al. Validation and psychometric assessment of a short clinical scale to measure chemotherapy-induced nausea and vomiting: the MASCC antiemesis tool. J Pain Symptom Manage. 2007;34(2):148-159.
8. Mertens WC, Higby DJ, Brown D, et al. Improving the care of patients with regard to chemotherapy-induced nausea and emesis: the effect of feedback to clinicians on adherence to antiemetic prescribing guidelines. J Clin Oncol. 2003;21(7):1373-1378.
9. Salsman J, Beaumont J, Rosenbloom S, et al. Communicating about chemotherapy-induced nausea and vomiting: a comparison of patient and provider perspectives. Support Care Cancer. 2009;17(1):884. Abstract.
10. Cohen L, de Moor CA, Eisenberg P, et al. Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings. Support Care Cancer. 2007;15(5):497-503.
11. Molassiotis A, Saunders MP, Valle J, et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer. 2008;16(2):201-208.
12. Storr MA, Sharkey KA. The endocannabinoid system and gut-brain signalling. Curr Opin Pharmacol. 2007;7(6):575-582.
13. Loprinzi C, Jatoi A. Antiemetic properties of megestrol acetate. J Palliat Med. 2006;9(2):239-240.
14. Navari RM, Brenner MC. Treatment of cancer-related anorexia with olanzapine and megestrol acetate: a randomized trial. Support Care Cancer. 2010;18(8):951-956.
15. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011;29(31):4189-4198.
16. Ettinger DS, Armstrong DK, Barbour S, et al. Antiemesis: clinical prac-tice guidelines in oncology. J Natl Compr Canc Netw. 2009;7(5):572-595.
17. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol. 2010;21(suppl 5):v232-v243.
18. Grunberg SM, Warr D, Gralla RJ, et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-state of the art. Support Care Cancer. 2011;19(suppl 1):S43-S47.
19. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14(10):1570-1577.
20. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98(11):2473-2482.
21. Grunberg S, Chua D, Maru A, et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol. 2011;29(11):1495-1501.
22. Roscoe JA, Morrow GR, Aapro MS, et al. Anticipatory nausea and vomiting. Support Care Cancer. 2011;19(10):1533-1538.
23. Kaiser R, Sezer O, Papies A, et al. Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes. J Clin Oncol. 2002;20(12):2805-2811.
24. Tremblay PB, Kaiser R, Sezer O, et al. Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol. 2003;21(11):2147-2155.
25. Hassan BA, Yusoff ZB. Genetic polymorphisms in the three Malaysian races effect granisetron clinical antiemetic actions in breast cancer patients receiving chemotherapy. Asian Pac J Cancer Prev. 2011;12(1):185-191.
26. Coates A, Abraham S, Kaye SB, et al. On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur J Cancer Clin Oncol. 1983;19(2):203-208.
27. Grunberg SM, Boutin N, Ireland A, et al. Impact of nausea/vomiting on quality of life as a visual analogue scale-derived utility score. Support Care Cancer. 1996;4(6):435-439.
28. Sun CC, Bodurka DC, Donato ML, et al. Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol. 2002;87(1):118-128.
29. IOM (Institute of Medicine). Patient-Centered Cancer Treatment Planning: Improving the Quality of Oncology Care: Workshop Summary. Washington, DC: The National Academies Press; 2011.
30. Berry DL, Blumenstein BA, Halpenny B, et al. Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol. 2011;29(8):1029-1035.
31. Given CW, Sikorskii A, Tamkus D, et al. Managing symptoms among patients with breast cancer during chemotherapy: results of a two-arm behavioral trial. J Clin Oncol. 2008;26(36):5855-5862.